Cargando…

Acute and Chronic Macrophage Differentiation Modulates TREM2 in a Personalized Alzheimer’s Patient-Derived Assay

Neuroinflammation plays a pivotal role in the pathogenesis of Alzheimer`s disease (AD). Brain macrophage populations differentially modulate the immune response to AD pathology according to the disease stage. Triggering receptor expressed on myeloid cells 2 (TREM2) is known to play a protective role...

Descripción completa

Detalles Bibliográficos
Autores principales: Cosma, Nicoleta-Carmen, Eren, Neriman, Üsekes, Berk, Gerike, Susanna, Heuser, Isabella, Peters, Oliver, Hellmann-Regen, Julian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333375/
https://www.ncbi.nlm.nih.gov/pubmed/37198381
http://dx.doi.org/10.1007/s10571-023-01351-7
_version_ 1785070639731703808
author Cosma, Nicoleta-Carmen
Eren, Neriman
Üsekes, Berk
Gerike, Susanna
Heuser, Isabella
Peters, Oliver
Hellmann-Regen, Julian
author_facet Cosma, Nicoleta-Carmen
Eren, Neriman
Üsekes, Berk
Gerike, Susanna
Heuser, Isabella
Peters, Oliver
Hellmann-Regen, Julian
author_sort Cosma, Nicoleta-Carmen
collection PubMed
description Neuroinflammation plays a pivotal role in the pathogenesis of Alzheimer`s disease (AD). Brain macrophage populations differentially modulate the immune response to AD pathology according to the disease stage. Triggering receptor expressed on myeloid cells 2 (TREM2) is known to play a protective role in AD and has been postulated as a putative therapeutic target. Whether, and to which extent TREM2 expression can be modulated in the aged macrophage population of the brain is unknown, emphasizing the need for a human, patient-specific model. Using cells from AD patients and matched controls (CO) we designed an assay based on monocyte-derived macrophages to mimic brain-infiltrating macrophages and to assess the individualized TREM2 synthesis in vitro. We systematically assessed the effects of short-term (acute—2 days) and long-term (chronic—10 days) M1- (LPS), M2- (IL-10, IL-4, TGF-β), and M0- (vehicle) macrophage differentiation on TREM2 synthesis. Moreover, the effects of retinoic acid (RA), a putative TREM2 modulator, on individualized TREM2 synthesis were assessed. We report increased TREM2 synthesis after acute M2- compared to M1-differentiation in CO- but not AD-derived cells. Chronic M2- and M0-differentiation however resulted in an increase of TREM2 synthesis in both AD- and CO-derived cells while chronic M1-differentiation increased TREM2 in AD-derived cells only. Moreover, chronic M2- and M0-differentiation improved the amyloid-β (Aβ) uptake of the CO-derived whereas M1-differentiation of the AD-derived cells. Interestingly, RA-treatment did not modulate TREM2. In the age of personalized medicine, our individualized model could be used to screen for potential drug-mediated treatment responses in vitro. GRAPHICAL ABSTRACT: Triggering receptor expressed on myeloid cells 2 (TREM2) has been postulated as a putative therapeutic target in Alzheimer’s disease (AD). Using cells from AD patients and matched controls (CO), we designed a monocyte-derived macrophages (Mo-MФs) assay to assess the individualized TREM2 synthesis in vitro. We report increased TREM2 synthesis after acute M2- compared to M1- macrophage differentiation in CO- but not AD-derived cells. Chronic M2- and M0- differentiation however resulted in an increase of TREM2 synthesis in both AD- and CO-derived cells while chronic M1-differentiation increased TREM2 in AD-cells only [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10571-023-01351-7.
format Online
Article
Text
id pubmed-10333375
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-103333752023-07-12 Acute and Chronic Macrophage Differentiation Modulates TREM2 in a Personalized Alzheimer’s Patient-Derived Assay Cosma, Nicoleta-Carmen Eren, Neriman Üsekes, Berk Gerike, Susanna Heuser, Isabella Peters, Oliver Hellmann-Regen, Julian Cell Mol Neurobiol Brief Report Neuroinflammation plays a pivotal role in the pathogenesis of Alzheimer`s disease (AD). Brain macrophage populations differentially modulate the immune response to AD pathology according to the disease stage. Triggering receptor expressed on myeloid cells 2 (TREM2) is known to play a protective role in AD and has been postulated as a putative therapeutic target. Whether, and to which extent TREM2 expression can be modulated in the aged macrophage population of the brain is unknown, emphasizing the need for a human, patient-specific model. Using cells from AD patients and matched controls (CO) we designed an assay based on monocyte-derived macrophages to mimic brain-infiltrating macrophages and to assess the individualized TREM2 synthesis in vitro. We systematically assessed the effects of short-term (acute—2 days) and long-term (chronic—10 days) M1- (LPS), M2- (IL-10, IL-4, TGF-β), and M0- (vehicle) macrophage differentiation on TREM2 synthesis. Moreover, the effects of retinoic acid (RA), a putative TREM2 modulator, on individualized TREM2 synthesis were assessed. We report increased TREM2 synthesis after acute M2- compared to M1-differentiation in CO- but not AD-derived cells. Chronic M2- and M0-differentiation however resulted in an increase of TREM2 synthesis in both AD- and CO-derived cells while chronic M1-differentiation increased TREM2 in AD-derived cells only. Moreover, chronic M2- and M0-differentiation improved the amyloid-β (Aβ) uptake of the CO-derived whereas M1-differentiation of the AD-derived cells. Interestingly, RA-treatment did not modulate TREM2. In the age of personalized medicine, our individualized model could be used to screen for potential drug-mediated treatment responses in vitro. GRAPHICAL ABSTRACT: Triggering receptor expressed on myeloid cells 2 (TREM2) has been postulated as a putative therapeutic target in Alzheimer’s disease (AD). Using cells from AD patients and matched controls (CO), we designed a monocyte-derived macrophages (Mo-MФs) assay to assess the individualized TREM2 synthesis in vitro. We report increased TREM2 synthesis after acute M2- compared to M1- macrophage differentiation in CO- but not AD-derived cells. Chronic M2- and M0- differentiation however resulted in an increase of TREM2 synthesis in both AD- and CO-derived cells while chronic M1-differentiation increased TREM2 in AD-cells only [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10571-023-01351-7. Springer US 2023-05-17 2023 /pmc/articles/PMC10333375/ /pubmed/37198381 http://dx.doi.org/10.1007/s10571-023-01351-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Brief Report
Cosma, Nicoleta-Carmen
Eren, Neriman
Üsekes, Berk
Gerike, Susanna
Heuser, Isabella
Peters, Oliver
Hellmann-Regen, Julian
Acute and Chronic Macrophage Differentiation Modulates TREM2 in a Personalized Alzheimer’s Patient-Derived Assay
title Acute and Chronic Macrophage Differentiation Modulates TREM2 in a Personalized Alzheimer’s Patient-Derived Assay
title_full Acute and Chronic Macrophage Differentiation Modulates TREM2 in a Personalized Alzheimer’s Patient-Derived Assay
title_fullStr Acute and Chronic Macrophage Differentiation Modulates TREM2 in a Personalized Alzheimer’s Patient-Derived Assay
title_full_unstemmed Acute and Chronic Macrophage Differentiation Modulates TREM2 in a Personalized Alzheimer’s Patient-Derived Assay
title_short Acute and Chronic Macrophage Differentiation Modulates TREM2 in a Personalized Alzheimer’s Patient-Derived Assay
title_sort acute and chronic macrophage differentiation modulates trem2 in a personalized alzheimer’s patient-derived assay
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333375/
https://www.ncbi.nlm.nih.gov/pubmed/37198381
http://dx.doi.org/10.1007/s10571-023-01351-7
work_keys_str_mv AT cosmanicoletacarmen acuteandchronicmacrophagedifferentiationmodulatestrem2inapersonalizedalzheimerspatientderivedassay
AT erenneriman acuteandchronicmacrophagedifferentiationmodulatestrem2inapersonalizedalzheimerspatientderivedassay
AT usekesberk acuteandchronicmacrophagedifferentiationmodulatestrem2inapersonalizedalzheimerspatientderivedassay
AT gerikesusanna acuteandchronicmacrophagedifferentiationmodulatestrem2inapersonalizedalzheimerspatientderivedassay
AT heuserisabella acuteandchronicmacrophagedifferentiationmodulatestrem2inapersonalizedalzheimerspatientderivedassay
AT petersoliver acuteandchronicmacrophagedifferentiationmodulatestrem2inapersonalizedalzheimerspatientderivedassay
AT hellmannregenjulian acuteandchronicmacrophagedifferentiationmodulatestrem2inapersonalizedalzheimerspatientderivedassay